2011
DOI: 10.1159/000328889
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical Efficacy and Toxicity Testing of Engineered Nanomaterials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2017
2017

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Much of current cancer research is focused on exploring novel targets and discovering new anticancer drugs. While the availability of new molecules certainly offers hope to patients who do not respond to existing drugs, development of each new molecule is associated with tremendous costs. , Many highly active drug candidates have been shelved because of poor physicochemical or pharmacokinetic characteristics. Reformulation of such molecules can overcome their unfavorable biological behavior and would offer a less expensive approach to anticancer drug development. ,, …”
Section: Introductionmentioning
confidence: 99%
“…Much of current cancer research is focused on exploring novel targets and discovering new anticancer drugs. While the availability of new molecules certainly offers hope to patients who do not respond to existing drugs, development of each new molecule is associated with tremendous costs. , Many highly active drug candidates have been shelved because of poor physicochemical or pharmacokinetic characteristics. Reformulation of such molecules can overcome their unfavorable biological behavior and would offer a less expensive approach to anticancer drug development. ,, …”
Section: Introductionmentioning
confidence: 99%